Renal Cell Carcinoma Drugs Market to Surpass USD 4.3 Billion Mark by 2021, Forecasts iGATE Research in New Report Available at

27 May 2016 • by Natalie Aster

LONDON – Currently, renal cell carcinoma hold a share of more than 2.8 percent of adult malignances and from 90 percent to 95 percent of neoplasms that arise from the kidney.

The world’s market for renal cell carcinoma drugs is forecast to overcome the USD 4.3 billion mark by 2021.

This growth will be ignited by a number of factors, such as rising incidence of this type of kidney cancer, population ageing, novel treatment options and strong pipeline candidates.

High prices for branded drugs restrain this market growth. Growing preference of generic drug variants is one more factor hampering the growth.

Sutent, Inyta, Nexavar and Votrient are some of the most commonly used drugs for treatment of the disease.

The largest share in the marketplace belongs to Sutent, but it may be dethroned by Votrient in the years to come since the latter one is expected to demonstrate the fastest growth in the offing.

Merck & Co., Eisai, Exelixis, Bionomics and Eli Lilly are amongst the largest companies in this space.

New research report “Renal Cell Carcinoma - Global Drugs Market Forecast and Pipeline Analysis to 2021” prepared by iGATE Research Pvt. Ltd. offers an in-depth analysis of the renal cell carcinoma marketplace. The report contains an insightful overview of this disease and covers its epidemiology in detail.

It includes epidemiological forecasts for the period 2012-2023. The report sheds light on diagnosed incident cases and diagnosed prevalent cases over the same period. The research study scrutinizes the drug market.

It profiles major branded drug products and focuses on sales trends. Company profiles are contained in this cutting-edge research report, as well. Driving forces and restraint are also discusses in the study.

More new reports by our partner are available at iGATE Research page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970